

CureVac – EBDC Conference Dresden

Dr. Achim Loehr, Director Business Development
07 October 2014

That is what we stand for



- World leading mRNA company with the longest and broadest experience in therapeutic mRNA technology
- First company to bring mRNA therapies to patients
- Unique capabilities to tailor and improve unmodified mRNA
- From concept to IND filing in a fraction of time compared to NBEs, and with higher probability of success
- Proven streamlined GMP process for rapid and cost effective mRNA production



CureVac – Development of mRNA-based Vaccines and Therapies

- Founded in 2000 as spin-off from University Tübingen, Germany
- Tübingen and Frankfurt, Germany
- ~ 130 FTEs
- Clinical trials in oncology (one Phase IIb) and infectious disease
- Key intellectual property with ~ 50 patent families
- Several strategic collaborations established

Major investor SAP co-founder Dietmar Hopp

- In total more than €145 million equity

We exploit our RNA technology for human protection and therapy



Protection Therapy

RNActive® Cancer Immunotherapy

Development of cancer immunotherapies against oncologic diseases with current clinical focus on prostate cancer and non-small cell lung cancer

RNActive® Prophylactic Vaccines

Use of RNActive® for the development of prophylactic vaccines against infectious diseases

RNAduvant®

Development of non-coding immunostimulating RNA as potent adjuvant for prophylactic and therapeutic vaccines




Our R&D pipeline




RNActive®

Prophylactic Vaccines




Cancer Immunotherapy



RNAdjuvant®




mRNA – An emerging new class with unparalleled potential



→ Our mRNA gives the body the information to produce its own drug

CureVac's RNAoptimizer™ provides unique mRNA product candidates





[!] CureVac has established a fast and efficient optimization process which is based on more than a decade of know-how in the mRNA field

RNActive[®] vaccines – self-adjuvanted two component vaccines with dual activity


Component 1 → Antigen Expression



Component 2 → Adjuvanticity



RNActive[®] vaccines



RNActive® Cancer Immunotherapy


USPs in Comparison to other Formats of Cancer Immunotherapy Vaccines



	CureVac RNAActive®	DNA plasmid cancer vaccine	Peptide based cancer vaccine	Dendritic cell cancer vaccine (autologous)	Vaccinia virus based cancer vaccine
Safety	✓	○	✓	○	○
Multiple antigens	✓	✓	✓	✓	○
Full length antigen	✓	✓	✗	✓	✓
Built-in adjuvant	✓	✗	✗	○	○
No HLA restriction	✓	✓	✗	✓	✓
Convenient	✓	✓	✓	✗	✓
Robust CMC	✓	✓	✓	✗	✗
CMC scalable	✓	✓	○	✗	✗

✓ no issues ○ potential issues ✗ clear issues

Our R&D pipeline RNActive® Cancer Immunotherapy



→ Multiple full length tumor antigens are delivered with our RNActive® development candidates

Antigen Cocktail of CV9104 against prostate carcinoma



Antigen Cocktail of CV9202 against NSCLC






RNActive® Prophylactic Vaccines

RNActive® Vaccines – Combination of Advantages of Established Vaccines plus Additional Benefits



Broad activation of the immune system




Safety due to minimal vector

Easy adaption of the gene sequence and stability

- + Stable at extreme temperatures – no need for cold chain logistics
- + GMP-production from de novo within a few weeks
- + One-for-all standardized and scalable production process, adaptable to novel vaccines within hours

Our R&D pipeline RActive® Prophylactic Vaccines




CureVac wins European Commission's € 2 Mio. Vaccine Prize 2014 for leap forward in vaccine technology

"RActive® vaccines have the ability to revolutionize the way vaccines will be developed, manufactured and distributed around the world."

Jury of the Vaccine Prize

RNAAdjuvant®

Our RNAdjuvant[®] pipeline



- Single-stranded non-coding RNA that is protected against degradation
- First human subject dosed
- Animal data
 - Enhances the immunogenicity of approved infectious disease vaccines allowing for dose sparing
 - Dramatically improves the immunogenicity of protein or peptide based vaccines resulting in potent anti-tumoral immune responses
 - Triggers 'balanced immune responses' comprising humoral and cellular effector responses and, importantly, memory responses
 - Shows very favorable safety characteristics

Thank You For Your Attention!



Giving the body the
information to produce
its own drug.

Visit us at www.curevac.com

Dr. Achim Loehr

Director Business Development

CureVac GmbH
Paul-Ehrlich-Straße 15
72076 Tübingen
Germany

Phone: +49 (0) 7071 - 9 20 53 - 196

Mobile: +49 (0) 1761 - 9 20 53 - 15

achim.loehr@curevac.com

www.curevac.com